Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Personal life == In 2003, Laidlaw said his favorite games included the Legend of Zelda series, Animal Crossing, Um Jammer Lammy, Castlevania: Symphony of the Night, Ico, Fatal Frame and Thief: The Dark Project. After leaving Valve, Laidlaw moved to Kauai, Hawaii. He moved to Los Angeles in 2020. He has an amateur radio license and his call sign is WH6FXC. Laidlaw also writes and records music.
Cholecystokinin tetrapeptide (CCK-4, tetragastrin, Trp-Met-Asp-Phe-NH2) is a peptide fragment derived from the larger peptide hormone cholecystokinin. Unlike cholecystokin which has a variety of roles in the gastrointestinal system as well as central nervous system effects, CCK-4 acts primarily in the brain as an anxiogenic, although it does retain some GI effects, but not as much as CCK-8 or the full length polypeptide CCK-58. CCK-4 reliably causes severe anxiety symptoms when administered to humans in a dose of as little as 50 μg, and is commonly used in scientific research to induce panic attacks for the purpose of testing new anxiolytic drugs. Since it is a peptide, CCK-4 must be administered by injection, and is rapidly broken down once inside the body so has only a short duration of action, although numerous synthetic analogues with modified properties are known.
Infectious disease, e.g., COVID-19, dengue, Ebola, gastroenteritis, HIV, influenza, Lyme disease, rocky mountain spotted fever, secondary syphilis, malaria, mononucleosis, as well as infections of the skin, e.g., abscesses and boils. Immunological diseases, e.g., relapsing polychondritis, autoimmune hepatitis, granulomatosis with polyangiitis, Horton disease, inflammatory bowel diseases, Kawasaki disease, lupus erythematosus, sarcoidosis, Still's disease, rheumatoid arthritis, lymphoproliferative disorders and psoriasis; Tissue destruction, as a result of cerebral bleeding, crush syndrome, hemolysis, infarction, rhabdomyolysis, surgery, etc.; Cancers, particularly blood cancers such as leukemia and lymphomas; Metabolic disorders, e.g., gout, and porphyria; Inherited metabolic disorder, e.g., Fabry disease. Adult and pediatric manifestations for the same disease may differ; for instance, in COVID-19, one metastudy describes 92.8% of adults versus 43.9% of children presenting with fever. In addition, fever can result from a reaction to an incompatible blood product.
However, in a preprint study, Carnegie Mellon University researchers tested the behavior of agents in a simulated software company and found that none of the agents could complete a majority of the tasks assigned to them. Other researchers had similar findings with Devin AI and other agents in both formal business settings and freelance work. In June 2025, CNN argued that CEOs's statements on AI replacing their employees were a strategy to "[keep] workers working by making them afraid of losing their jobs." Tech companies have pressured employees to use generative AI models in their work, including AI coding agents. Brian Armstrong, the CEO of Coinbase, fired several employees who did not. Some business leaders have replaced some of their employees with agents, but have said that the agents would need more supervision than those employees. In October 2025, Futurism questioned whether Amazon's previously announced efforts to replace parts of its workforce with generative AI and AI agents could have led to the October 2025 outage of Amazon Web Services. Large technology companies such as Salesforce, Klarna and IBM announced layoffs in 2025, replacing hundreds of their employees in human resources or customer service with AI agents. However, Klarna later rehired several human employees. Yoshua Bengio warned at the 2025 World Economic Forum that "all of the catastrophic scenarios with AGI or superintelligence happen if we have agents". Financial authorities have warned that more complex and autonomous "agentic" AI could become a channel for systemic risk in finance.
For example, in the figure showing trypanothione reductase from the human protozoan parasite Trypanosoma cruzi, two molecules of an inhibitor called quinacrine mustard are bound in its active site. The top molecule is bound reversibly, but the lower one is bound covalently as it has reacted with an amino acid residue through its nitrogen mustard group.
Sources: en.wikipedia.org
=== Cookbooks === Buwei Yang Chao. How to Cook and Eat in Chinese. (New York: John Day, 1945; revisions and reprints). Fuchsia Dunlop. Land of Plenty: A Treasury of Authentic Sichuan Cooking. (New York: Norton, 2003). ISBN 0393051773. Fuchsia Dunlop. Revolutionary Chinese Cookbook: Recipes from Hunan Province. (New York: Norton, 2007). ISBN 0393062228. Fuchsia Dunlop. Shark's Fin and Sichuan Pepper: A Sweet-Sour Memoir of Eating in China. (New York: Norton, 2008). ISBN 9780393066579. Chinese cook book by Vernon Galster Emily Hahn, Recipes, The Cooking of China. (Alexandria, Va.: Time-Life Books, Foods of the World, 1981). Hsiang-Ju Lin and Tsuifeng Lin. Chinese Gastronomy. (London: Nelson, 1969; rpr.). ISBN 0171470575. Yan-Kit So. Classic Food of China. (London: Macmillan, rpr 1994, 1992). ISBN 9780333576717. Martin Yan. Martin Yan's Chinatown Cooking: 200 Traditional Recipes from 11 Chinatowns around the World. (New York: Morrow, 2002). ISBN 0060084758. Georgina Freedman. Cooking South of The Clouds: Recipes and Stories From China's Yunnan Province. (Octopus; Kyle, 2018). ISBN 9780857834980.
=== Continuing Claim === His only son, Ernest Augustus, Crown Prince of Hanover, inherited the claim upon George's death in 1878. Ernest Augustus was also first in line to the throne of the Duchy of Brunswick, whose rulers had been a junior branch of the House of Hanover. In 1884, that branch became extinct with the death of William, a distant cousin of Ernest Augustus. Since Ernest Augustus refused to renounce his claim to annexed Hanover, the Bundesrat of the German Empire ruled that he would disturb the peace of the empire if he ascended the throne of Brunswick. As a result, Brunswick was ruled by a regency until 1913, when his son, also named Ernest Augustus, married the German Emperor's daughter, Princess Viktoria Luise and swore allegiance to the German Empire. The Duke then renounced his claim to Brunswick in favour of his son, and the Bundesrat allowed the younger Ernest Augustus to take possession of Brunswick as a kind of dowry compensation for Hanover. The German-Hanoverian Party, which at times supported secession from the Reich, demanded a separate status for the province in the Reichstag. The party existed until banned by the Nazi government.
== Distribution == Hydrothermal vents are distributed along the Earth's plate boundaries, although they may also be found at intra-plate locations such as hotspot volcanoes. As of 2009 there were approximately 500 known active submarine hydrothermal vent fields, with about half visually observed at the seafloor and the other half suspected from water column indicators and/or seafloor deposits.
Tachykinin peptides are also involved in inflammation, and tachykinin receptor antagonists have been researched for use in treating inflammatory conditions such as asthma and irritable bowel syndrome. The main use for which these antagonist drugs have been applied so far, however, is as antiemetics, in both human and veterinary medicine. Examples of tachykinin antagonists include:
Sources: en.wikipedia.org
Various authorities (e.g. ITIS 16, GRIN 27, WCSP, NCBI, DELTA) differ on the exact number of genera included in Liliaceae s.s., but generally there are about fifteen to sixteen genera, depending on whether or not Amana is included in Tulipa and Lloydia in Gagea. Currently the APWeb lists fifteen genera, arranged as shown in this table:
forward genetics An experimental approach in molecular genetics in which a researcher starts with a specific known phenotype and attempts to determine the genetic basis of that phenotype by any of a variety of laboratory techniques, commonly by inducing random mutations in the organism's genome and then screening for changes in the phenotype of interest. Observed phenotypic changes are assumed to have resulted from the mutation(s) present in the screened sample, which can then be mapped to specific genomic loci and ultimately to one or more specific candidate genes. This methodology contrasts with reverse genetics, in which a specific gene or its gene product is individually manipulated in order to identify the gene's function.
== Regulatory harmonization == In an effort to reduce the burden on manufacturers applying for orphan drug status, the FDA and the European Medicines Agency (EMA) agreed in late 2007 to utilize a common application process for both agencies. However, the two agencies will continue to maintain separate approval processes.
Low-level laser therapy (LLLT), cold laser therapy, or photobiomodulation (PBM) is a photochemical reaction-based medical treatment that applies low-level (low-power) lasers or light-emitting diodes (LEDs) to the surface of the body without damaging tissue. Proponents claim that this treatment stimulates healing, relieves pain, and enhances cell function. Sometimes termed as low-level red-light therapy (LLRL), its effects appear to be limited to a specific range of wavelengths. Its effectiveness is under investigation. Several such devices are cleared by the United States Food and Drug Administration (FDA). The therapy may be effective for conditions such as juvenile myopia, rheumatoid arthritis, and oral mucositis.
^A The carbohydrate figure is calculated in the United States Department of Agriculture database and does not always correspond to the sum of the sugars, the starch, and the dietary fibre. ^B The fructose to fructose plus glucose ratio is calculated by including the fructose and glucose coming from the sucrose.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.